Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, C. G. | - |
dc.contributor.author | Lee, H. | - |
dc.contributor.author | Choi, J. W. | - |
dc.contributor.author | Lee, S. J. | - |
dc.contributor.author | Kim, S. H. | - |
dc.contributor.author | Lim, H. E. | - |
dc.date.accessioned | 2021-09-08T01:17:47Z | - |
dc.date.available | 2021-09-08T01:17:47Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2010-08 | - |
dc.identifier.issn | 0946-1965 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/115985 | - |
dc.description.abstract | Objectives: To explore if non-concurrent amlodipine dosing results in less drug interaction, the pharmacokinetic profiles, safety and efficacy endpoints were assessed following repeated doses of simvastatin, co-administered concurrently or non-concurrently with amlodipine in patients with coexisting hypertension and hyperlipidemia. Methods: Seventeen patients randomly received daily doses of 20 mg simvastatin and 5 mg amlodipine for 6 weeks, either with both drugs at 7:00 PM (concurrent) or with simvastatin at 7:00 PM followed by amlodipine at 11:00 PM (non-concurrent). The maximum plasma concentration (C-max) and the area under the concentration-time curve up to the last quantifiable concentration (AUC(last)) were estimated at steady state. Lipid profiles and blood pressure values were also compared between the concurrent and non-concurrent groups. Results: The C-max and AUC(last) and of simvastatin acid in the non-concurrent amlodipine dosing group were 63.2% and 66.0%, respectively, of the values obtained in the concurrent group (1.2 +/- 1.0 vs. 1.9 +/- 0.9 ng/ml and 10.3 +/- 8.3 vs. 15.6 +/- 7.5 h ng/ml, respectively, mean standard deviation). Changes from baseline in lipid profile and blood pressure were comparable between the groups. Conclusions: Non-concurrent dosing may be a useful and safe therapeutic option for patients who require two or more drugs administered concomitantly, but who are likely to develop unwanted drug interactions. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | DUSTRI-VERLAG DR KARL FEISTLE | - |
dc.subject | DRUG-DRUG INTERACTION | - |
dc.subject | PLASMA-CONCENTRATIONS | - |
dc.subject | ACID | - |
dc.subject | GEMFIBROZIL | - |
dc.subject | DILTIAZEM | - |
dc.subject | BIOEQUIVALENCE | - |
dc.subject | CERIVASTATIN | - |
dc.subject | INHIBITION | - |
dc.subject | VOLUNTEERS | - |
dc.subject | METABOLISM | - |
dc.title | Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, C. G. | - |
dc.contributor.affiliatedAuthor | Kim, S. H. | - |
dc.contributor.affiliatedAuthor | Lim, H. E. | - |
dc.identifier.scopusid | 2-s2.0-77955703973 | - |
dc.identifier.wosid | 000281130800001 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, v.48, no.8, pp.497 - 503 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.volume | 48 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 497 | - |
dc.citation.endPage | 503 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | DRUG-DRUG INTERACTION | - |
dc.subject.keywordPlus | PLASMA-CONCENTRATIONS | - |
dc.subject.keywordPlus | ACID | - |
dc.subject.keywordPlus | GEMFIBROZIL | - |
dc.subject.keywordPlus | DILTIAZEM | - |
dc.subject.keywordPlus | BIOEQUIVALENCE | - |
dc.subject.keywordPlus | CERIVASTATIN | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | VOLUNTEERS | - |
dc.subject.keywordPlus | METABOLISM | - |
dc.subject.keywordAuthor | non-concurrent dosing | - |
dc.subject.keywordAuthor | amlodipine | - |
dc.subject.keywordAuthor | simvastatin | - |
dc.subject.keywordAuthor | drug interaction | - |
dc.subject.keywordAuthor | cytochrome P-450 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.